Hematology Frontier

The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, remains the largest and most comprehensive international academic gathering in the field of hematology. Every year, it draws leading experts and scholars from across the globe for in-depth discussions and exchanges on groundbreaking research. This year, the lymphoma field witnessed several pivotal study outcomes. Oncology Frontier - Hematology Frontier invited Dr. Jun Shi from The Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, to provide a detailed analysis and commentary on two highly impactful studies presented during the meeting.

Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, ineffective hematopoiesis, refractory cytopenia, and a potential progression to acute myeloid leukemia (AML). At the 2024 Annual Meeting of the American Society of Hematology (ASH), held from December 7 to 10 in San Diego, numerous studies on MDS were presented, showcasing significant progress in the treatment and prognostic evaluation of low-risk MDS. Oncology Frontier - Hematology Frontier invited Dr. Huaquan Wang from Tianjin Medical University General Hospital to provide expert commentary on the most impactful research in this field, delivering cutting-edge insights to our readers.

The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, continues to be a global focal point for clinicians and researchers in hematology. As one of the most prestigious international conferences in the field, it has captured widespread attention both globally and within China. To provide timely updates on the most significant developments at the conference, Oncology Frontier - Hematology Frontier launched the "ASH Daily News Highlights" series. Dr. Jun Zhu from Peking University Cancer Hospital serves as the series host, connecting daily with onsite experts to bring firsthand updates. On the third day of the conference, we were honored to hear from Dr. Wenming Chen of Beijing Chaoyang Hospital, who shared insights into key studies in the field of myeloma.

Myelodysplastic Syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenia, and the potential to transform into acute myeloid leukemia (AML). At the 2024 American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 7th to 10th, numerous studies in the field of MDS were announced, with significant progress particularly in the treatment and prognosis assessment of low-risk MDS. "Hematology Frontier" specially invited Dr. Huaquan Wang from the Department of Hematology, Tianjin Medical University General Hospital, to select and comment on the key studies, in hopes of bringing cutting-edge information and unique insights to everyone.

Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with patient survival ranging from a few months to several decades. Therefore, after the diagnosis of CLL, it is particularly important to conduct an accurate and comprehensive prognostic assessment for patients. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7th to 10th, some research results on prognostic factors of CLL were announced. "Hematology Frontier" specially invited Dr. Shenmiao Yang from the Peking University Institute of Hematology, to select key studies from the conference and provide insightful commentary, aiming to offer valuable references and insights to colleagues in the field.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts leading global experts to discuss groundbreaking research and advancements. This year, Dr. He Huang’s team from the Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, had 20 studies selected for presentation, including eight as oral presentations. Their achievements not only highlighted their exceptional contributions but also delivered valuable research findings and innovative strategies to the global academic community.

The 2024 Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10 in San Diego, USA. As one of the foremost global gatherings in the field of hematology, this prestigious conference attracted the attention of clinicians and researchers worldwide, including a keen audience from China. To bring the latest and most significant updates from the conference to readers promptly, Oncology Frontier - Hematology Frontier launched a special daily column titled ASH News Broadcast · Highlights of the Day. Hosted by Dr. Jun Zhu from Peking University Cancer Hospital, the series connects with on-site experts to deliver firsthand insights. We had the privilege of speaking with Dr. Qian Jiang from Peking University People's Hospital, who shared her thoughts on the key highlights and standout presentations.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7 to 10, 2024, in San Diego, USA. Renowned as the largest international academic event in hematology, the conference showcased cutting-edge research and the latest advancements in drug development, representing the highest academic standards in the field. At this prestigious event, Dr. Huafeng Wang’s team from The First Affiliated Hospital of Zhejiang University School of Medicine presented four impactful studies. These investigations spanned new therapeutic strategies for myelodysplastic syndrome (MDS) and insights into the mechanisms, potential treatments, and prognostic implications for acute myeloid leukemia (AML). To delve deeper into these findings, Oncology Frontier - Hematology Frontier invited Professor Wang to provide expert commentary and analysis.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As one of the largest and most prestigious international conferences in the field of hematology, ASH highlighted groundbreaking advancements and new drug development data, showcasing the highest levels of academic research globally. Platelet delay or engraftment failure is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Strategies to accelerate platelet engraftment remain a critical clinical challenge. At this year’s ASH meeting, Dr. Erlie Jiang and his team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) presented findings from their study (Abstract #266) investigating the effects of elevated recombinant human thrombopoietin (rhTPO) dosing on platelet engraftment in allo-HSCT. Hematology Frontier interviewed Prof. Jiang to explore the research findings and their implications.

Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10, Dr. Mingfeng Zhao from Tianjin First Central Hospital presented groundbreaking findings on a novel iCAR-T therapy for AML, offering renewed hope for patients. Hematology Frontier had the privilege of inviting Prof. Zhao to discuss this study and share insights on his team’s future research plans.